Article Information
History
- May 25, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Mohamed A. Kamal1,*,†,
- Andreas Kuznik1,†,
- Luyuan Qi2,†,
- Witold Więcek3,
- Mohamed Hussein1,
- Hazem E. Hassan1,
- Kashyap Patel4,
- Thomas Obadia2,
- Masood Khaksar Toroghi1,
- Daniela J. Conrado1,
- Nidal Al-Huniti1,
- Roman Casciano4,
- Meagan P. O’Brien1,
- Ruanne V. Barnabas5,
- Myron S. Cohen6,* and
- Patrick F. Smith4,*
- 1Regeneron Pharmaceuticals; Tarrytown, NY, USA
- 2Certara; Paris, France
- 3Certara; London, United Kingdom
- 4Certara; Princeton, New Jersey, USA
- 5Department of Global Health, University of Washington; Seattle, Washington, USA
- 6Institute for Global Health and Infectious Diseases, University of North Carolina; Chapel Hill, North Carolina, USA
- ↵*Corresponding authors. Email: mohamed.kamal{at}regeneron.com; myron_cohen{at}med.unc.edu; patrick.smith{at}certara.com
↵† These authors contributed equally to this work
Posted May 25, 2021.
Monoclonal Antibody Treatment, Prophylaxis and Vaccines Combined to Reduce SARS CoV-2 Spread
